
BIO
USDBio-Rad Laboratories Inc. Class A Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$309.870
Kõrge
$316.200
Madal
$301.920
Maht
0.18M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
8.3B
Tööstusharu
Meditsiiniseadmed
Riik
United States
Kauplemisstatistika
Keskmine maht
0.24M
Börs
NYQ
Valuuta
USD
52 nädala vahemik
Tehisintellekti analüüsiaruanne
Viimati uuendatud: 1. nov 2025BIO Stock Alert: Bio-Rad Laboratories Shows Short-Term Opportunity Amid Volatility
Breaking Down the Current Picture
Bio-Rad Laboratories (BIO) just wrapped up a wild October. The stock surged from $280 to $340 in three weeks, then crashed 6% in a single day after earnings. Today it’s sitting at $319.55--down from its October peak but still 5% above where it started the month. Let’s cut through the noise.
What the News Tells Us
- Analyst split is real: Citigroup doubled down with a $375 target (22% upside), while Wells Fargo stayed cautious at $340 despite raising their forecast.
- Earnings disappointment: The October 29 report triggered immediate selling. No details were provided in the data, but the timing aligns with BIO’s sharp 6% drop that day.
- Sentiment is neutral overall--bullish upgrades are fighting against weak fundamentals.
Price Action Decoded
Here’s what the chart whispers:
- The $340 wall matters: BIO tested this level twice in late October (Oct 21 and 24) but couldn’t break through. Each time, heavy selling followed.
- Support at $318.50 is make-or-break: Yesterday’s close ($319.55) barely held above this technical floor. Volume spiked to 510K shares on the drop (Oct 29)--more than double its average.
- That "bullish" MACD crossover? It happened at $322 on Oct 15, but the stock stalled anyway. Technicals alone won’t drive this move.
Where It’s Headed Next
Short-term signals are messy: ✅ Bullish spark: Current price hovering at the Bollinger Band lower limit ($318.51) often triggers bounces. ⚠️ Red flags: Negative ROE (-9.5%) and sky-high debt (20.7 D/E ratio) scream "fundamental trouble." 🔮 AI’s mixed forecast: +0.5% tomorrow → -0.3% the next day → +0.9% on day 3. Translation: Choppy trading ahead.
Actionable Guidance
For traders only--this isn’t a long-term hold.
Entry Strategy
- Best window: $317-$319.50 (yesterday’s low was $315.10--don’t chase below that).
- Why now?: Extreme volume on the drop (510K shares) suggests panic selling washed out.
- Critical trigger: Wait for a 15-minute candle closing above $322 to confirm reversal.
Exit Plan
- Take profit: $342 (Wells Fargo’s target). Anything beyond $345 faces serious resistance.
- Stop loss: $314.50 (1.5% below yesterday’s low). Do not move this lower.
- Time limit: Max 10 trading days. This setup dies if the $318 support breaks.
Who Should Skip This
- Long-term investors: Debt and negative ROE are structural issues.
- Risk-averse traders: The 6% single-day swing shows BIO isn’t for the faint of heart.
- Anyone needing stability: This stock moves on earnings whispers and analyst notes--not steady growth.
Bottom Line
BIO is a short-term scalp, not a portfolio cornerstone. The $318 support level is the fulcrum. If it holds with volume
Seotud uudised
Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375
Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories with a Buy and raises the price target from $350 to $375.
Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340
Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories with a Equal-Weight and raises the price target from $265 to $340.
Bio-Rad Reports Third-Quarter 2025 Financial Results
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. "During the third
Tehisintellekti ennustusBeta
Tehisintellekti soovitus
Uuendatud kell: 5. nov 2025, 03:27
66.2% Kindlus
Risk ja kauplemine
Sisenemispunkt
$308.48
Võta kasum
$317.74
Peata kahjum
$280.36
Põhitegurid
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.